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Abstract
 
Hemofiltrate CC chemokine (HCC)-1 is a recently described human chemokine that is consti-
tutively expressed in numerous tissues and is present at high concentrations in normal plasma.
Using a cell line expressing CC chemokine receptor (CCR)5 as a bioassay, we isolated from
human hemofiltrate an HCC-1 variant lacking the first eight amino acids. HCC-1[9–74] was a
potent agonist of CCR1, CCR3, and CCR5 and promoted calcium flux and chemotaxis of T
lymphoblasts, monocytes, and eosinophils. It also blocked entry of HIV-1 strains using CCR5
as coreceptor. Limited tryptic digestion of HCC-1 generated the active variant. Conditioned
media from several tumor cell lines activated HCC-1 with a high efficiency, and this activity
could be inhibited by serine protease inhibitors. Our results indicate that HCC-1 represents a
nonfunctional precursor that can be rapidly converted to the active chemokine by proteolytic
processing. This process represents an additional mechanism by which tumor cells might gen-
erate chemoattractant molecules and recruit inflammatory cells. It might also affect HIV-1 rep-
lication in infected individuals and play an important role in AIDS pathogenesis.
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Introduction
 
Chemokines constitute a superfamily of small (8–10 kD)
secreted cytokines that mediate chemotaxis, trafficking, and
activation of leukocyte populations. From a structural
viewpoint, they are classified into two major subgroups,
CC and CXC chemokines, according to the relative posi-
tion of the first two of four conserved cysteine residues (1).
From a functional viewpoint, they may be classified into
inflammatory chemokines, which are mostly regulated at
the transcriptional level and involved in the recruitment of
leukocytes to inflammatory sites, and constitutive chemo-
kines, which are responsible for the trafficking and homing
of leukocyte populations (1, 2). Chemokines mediate their
activity through G protein–coupled receptors and pertussis
toxin–sensitive heterotrimeric G proteins of the G
 
i
 
 family
(3). Most chemokine receptors are promiscuous, binding
and responding functionally to a variety of chemokines,
and many chemokines activate several receptors (4). The
constitutive or regulated expression of chemokines by vari-
ous cell types and the pattern of receptor distribution on
immune cell populations determine the range of activities
these mediators play in leukocyte trafficking (2). Besides
their role in the recruitment of leukocytes, chemokines
have been shown to be involved in an increasing range of
other functions, including the control of hematopoiesis (5)
and angiogenesis (6). Accordingly, chemokine receptors are
expressed on a variety of cell types besides leukocyte popu-
lations, including epithelial (7), smooth muscle (8), and en-
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dothelial cells (6). Chemokines and their receptors play
major roles in tumorigenesis. Monocyte chemotactic pro-
tein (MCP)
 
1
 
-1 and other chemokines are produced by var-
ious tumors and account for the infiltration of these tumors
by host inflammatory cells (9). Chemokine receptors
(mainly CCR5 and CXCR4) were also shown to consti-
tute the coreceptors for HIV (10). CCR5 is the major
coreceptor for the macrophage-tropic strains of HIV (11–
14) that are responsible for disease transmission. Chemo-
kines acting on CCR5, including RANTES (regulated upon
activation, normal T cell expressed and secreted), macro-
phage inflammatory protein (MIP)-1
 
a
 
, MIP-1
 
b
 
, and MCP-2
were shown to inhibit HIV-1 entry (15, 16). Considerable
efforts are currently underway to explore the therapeutic
properties of chemokines, chemokine analogues, mAbs, or
chemical ligands acting on CCR5 as antiviral agents (3)
 
.
 
Hemofiltrate CC chemokine (HCC)-1 is a member of
the CC chemokine family, originally isolated from hemo-
filtrate of patients with chronic renal failure (17). HCC-1
consists of 74 amino acids, after cleavage of a 19-residue
leader sequence, and shares 46% sequence identity with
MIP-1
 
a
 
 and MIP-1
 
b
 
. Its gene (
 
SCYA14
 
) is colocalized
with other CC chemokine genes in a cluster located in the
17q11.2 region of the human genome (18). Two unusual
features of HCC-1 are its constitutive expression in a large
variety of tissues and its high concentration range, which is
1.5–10 nM in normal human plasma and 2.5–80 nM in
plasma from patients with chronic renal failure (17). How-
ever, the major source for circulating HCC-1 is unknown.
HCC-1 was described as a weak activator of monocytes
(17), and CCR1 was later identified as responding func-
tionally to high (and supraphysiological) concentrations of
HCC-1 (19).
In this report, we describe the purification from hemofil-
trate of a new high-affinity CCR5 ligand and its character-
ization as a truncated form of HCC-1. This variant, result-
ing from the proteolytic processing of the precursor, was
also found to be highly active on CCR1 and CCR3 to ac-
tivate and recruit monocytes, T lymphoblasts, and eosino-
phils and to block HIV entry.
 
Materials and Methods
 
Materials.
 
All chemicals, including protease inhibitors, were
obtained from Sigma-Aldrich unless stated. Cell culture media
were from GIBCO BRL, chemokines were from R & D Sys-
tems, and radioligands were from Amersham Pharmacia Biotech.
Primary cell lines were obtained from the American Type Cul-
ture Collection.
 
Aequorin Assays.
 
CHO-K1 cell lines expressing chemokine
receptors G
 
a
 
16
 
 and mitochondrial apoaequorin were established.
A functional assay based on the luminescence of mitochondrial
aequorin after intracellular Ca
 
2
 
1
 
 release (20) was performed as de-
 
scribed (21). In brief, cells were collected from plates with PBS
containing 5 mM EDTA, pelleted, and resuspended at 10
 
7
 
 cells/
ml in DMEM-F12 medium and incubated with 5 
 
m
 
M coelenter-
azine H (Molecular Probes) for 4 h at room temperature. Cells
were then washed in DMEM-F12 medium and resuspended at a
concentration of 2 
 
3
 
 10
 
6
 
 cells/ml. Cells were then mixed with
the chemokines, and the light emission was recorded over 30 s
using a Microlumat™ luminometer (PerkinElmer). Results are
expressed as relative light units (RLU).
 
Purification of HCC-1[9–74].
 
Peptides were extracted from
10,000 liters of human hemofiltrate derived from 40 adult pa-
tients with chronic renal disease and fractionated by strong cation
exchange chromatography as previously reported (22). The re-
sulting fractions were subjected to reverse-phase (RP)
 
 
 
chroma-
tography (Source RPC column; 15 
 
m
 
m, 10 
 
3
 
 12.5 cm; Amer-
sham Pharmacia Biotech) as a second separation step (0–50%
acetonitrile, 10 mM HCl, 200 ml/min). Fractions of 200 ml were
collected and tested for their ability to stimulate CCR5. Active
fractions were subsequently separated by four further analytical
RP-HPLC steps using techniques described elsewhere (23). Mass
determination of the biologically active compounds was carried
out on a Sciex API III quadrupole mass spectrometer (Perkin-
Elmer) with an electrospray interface (ESI-MS) and with a La-
serTec RBT II MALDI-MS (PerSeptive Biosystems). Sequence
analysis was performed on a 473 A gas-phase sequencer (Applied
Biosystems) by Edman degradation with on-line detection of
phenylthiohydantoin amino acids.
 
Synthesis of HCC-1[9–74].
 
HCC-1[9–74] was prepared by
Fmoc solid-phase peptide synthesis as described (24). The puri-
fied product was characterized by HPLC, capillary zone electro-
phoresis, electrospray mass spectrometry, and sequence analysis
and was used for biological testing according to the net peptide
content as determined by amino acid analysis.
 
Radioligand Binding Assays.
 
Competition binding assays were
performed as described (21, 25) on crude membrane fractions
prepared from CHO-K1 cell lines expressing CCR5 or CCR1
and a K562 cell line expressing CCR3. In brief, 1–10 
 
m
 
g crude
membrane extracts were incubated in binding buffer (50 mM
HEPES, pH 7.4, 5 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, and 0.5% [wt/vol]
protease-free BSA) containing 0.1 nM radioligand 
 
125
 
I–MIP-1
 
a
 
,
 
125
 
I–RANTES, or 
 
125
 
I–eotaxin and competitors over 90 min at
27
 
8
 
C. Bound tracer was separated by filtration through GF/B fil-
ters (Millipore) presoaked in 1% BSA or 0.3% polyethylenimine.
Filters were then counted by gamma scintillation counting. Re-
sults were normalized for total binding in the absence of compet-
itor (100%) and nonspecific binding (0%) in the presence of a
100-fold excess of the competitor and were analyzed by nonlin-
ear regression using a single-site competition model (Graph-Pad
Prism™ Software).
 
Calcium and Chemotactic Assays.
 
Donor blood buffy coats for
the isolation of neutrophils, monocytes, and lymphocytes were
supplied by the Central Laboratory of the Hôpital Erasme (Brus-
sels, Belgium). Eosinophils were purified from the venous blood
of healthy volunteers by using a negative selection based on
CD16 microbeads (Miltenyi Biotec) and further isolated accord-
ing to established methods (26). Lymphoblasts were cultured as
described (27), and 
 
z
 
60% of the cells expressed CCR5, as deter-
mined by flow cytometry using the 2D7 mAb (R & D Systems).
For intracellular calcium measurements, the cells were loaded for
30 min at room temperature with Fura-2AM (Molecular Probes).
Calcium transients were monitored by a LS 50B spectrofluorime-
ter (PerkinElmer) as described (28). Chemotaxis was assessed in
48-well chambers using polycarbonate filter membranes with
 
1
 
Abbreviations used in this paper:
 
 HCC, hemofiltrate CC chemokine; MCP,
monocyte chemotactic protein; MIP, macrophage inflammatory protein;
RANTES, regulated upon activation, normal T cell expressed and se-
creted. 
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5-
 
m
 
M pores (Neuroprobe Inc.) as previously described (29). The
results are represented as chemotactic index.
 
HIV Infection Assays.
 
P4-CCR5 cells (National Institutes of
Health AIDS Research and Reference Reagent program; refer-
ence 30) were grown in DMEM supplemented with 10% FCS
and 1 
 
m
 
g/ml puromycin (GIBCO BRL). Cells were seeded in
flat-bottomed 96-well dishes, cultured overnight, and incubated
with the chemokines for 2 h before infection with virus contain-
ing 20 ng of p24 antigen in a total volume of 50 
 
m
 
l of medium.
After overnight incubation, cells were washed twice and culti-
vated in fresh DMEM without chemokines. 3 d after infection,
the cells were lysed, and 
 
b
 
-galactosidase activity (Tropix) was
measured. PBMCs were isolated using lymphocyte separation
medium (Organon Teknika Corporation). Cells were cultured in
RPMI 1640 medium with 20% FCS (GIBCO BRL) and 50 U/ml
IL-2 (Chiron Corp.), and virus production was measured by a re-
verse transcriptase assay as described (31).
 
Activation of HCC-1 by Conditioned Media.
 
Human tumoral
cell lines DU-145 (HTB-81), 143B (CRL-8303), MCF-7
(HTB-22), and MeWo were maintained in MEM supplemented
with 10% FCS. For the screening of these cell lines for pro-
teolytic activities on HCC-1, 3 
 
3
 
 10
 
6
 
 cells were plated in 9-cm
dishes and grown for 48 h to 70–80% confluence, at which time
1 
 
m
 
M HCC-1[1–74] was added to the medium. After an incuba-
tion at 37
 
8
 
C for 48 h, the medium was collected, clarified by cen-
trifugation at 13,000 
 
g
 
, and stored at 
 
2
 
80
 
8
 
C until testing on the
CCR5-expressing and control CHO cells using the aequorin-
based assay. Conditioned medium was prepared from DU-145
cells for testing the activity of protease inhibitors. Serum-free me-
dium was incubated for 5 d with confluent cultures and clarified
by centrifugation and 0.22-
 
m
 
m filtration. This conditioned me-
dium was incubated with HCC-1[1–74] alone or in the presence
of protease inhibitors for 6 h at 37
 
8
 
C and tested immediately on
CCR5-expressing cells. Potential interference of the protease in-
hibitors with the aequorin assay was excluded by testing their ef-
fect on the response to 2 nM HCC-1[9–74]. Non–CCR5-spe-
cific activities of conditioned media and protease inhibitors were
assayed on CHO cell lines expressing no chemokine receptors.
 
Results
 
In the process of isolating natural ligands of various G
protein–coupled receptors from human hemofiltrate frac-
tions, we used, among others, a cell line expressing human
CCR5. Hemofiltrate was fractionated by cation exchange
and RP chromatography. A peak of biological activity spe-
cific for CCR5-expressing cells was obtained (Fig. 1 a) and
was further purified by additional chromatographic steps.
After the last step (Fig. 1 b), the active fraction was ana-
lyzed by mass spectrometry, revealing two major compo-
nents with molecular masses of 8,673 and 7,795 daltons.
Edman degradation identified the NH
 
2
 
-terminal sequences
TKTESSSRGPYHP and GPYHPSEXXFTYT. These
data corresponded respectively to full size human HCC-1
and to a variant of the same protein, HCC-1[9–74], trun-
cated after an arginine residue (Fig. 1 e). As full size HCC-1
is inactive on CCR5 (19, 21), we focused on HCC-1[9–
74]. We investigated whether trypsin could generate this
variant by performing a limited tryptic digestion of full size
HCC-1 highly purified from another hemofiltrate batch
and testing the biological activity at various time points.
 
The activity of the tryptic digest increased progressively
(Fig. 1 c), and analysis of the products by RP chromatogra-
phy, mass spectrometry, and sequencing identified HCC-
1[9–74] (7,795 daltons) as the single active compound (Fig.
1 d). Chemical synthesis of HCC-1[9–74] further con-
firmed the biological activity of the truncated chemokine
on a CCR5-expressing cell line. Both the purified
chemokine variant and chemically synthesized HCC-1[9–
74] were used for further characterization of the molecule.
The activity of HCC-1[9–74] was tested on CCR5 and
other chemokine receptors using an aequorin-based assay.
The truncated chemokine appeared as a high-affinity ago-
nist of CCR5 (EC
 
50 
 
4.8 
 
6
 
 1.2 nM) with a potency similar
to that of RANTES and MIP-1
 
a
 
 (Fig. 2 and Table I). It
was also more active than RANTES on CCR1 (EC
 
50 
 
2.8 
 
6
 
0.8 nM) and a reasonably good agonist for CCR3 (EC
 
50
 
78 
 
6
 
 14 nM), whereas it was inactive on CCR2, CCR4,
CCR6, CCR7, CCR8, CCR9, CXCR1, and CX3CR1.
The properties of HCC-1[9–74] were confirmed by com-
petition radioligand binding assays on CCR1, CCR3, and
CCR5. The binding parameters were consistent with the
functional data (Fig. 2 and Table I). The affinity of HCC-
1[9–74] for CCR5 (
 
K
 
i 
 
0.04 
 
6
 
 0.01 nM) was similar to that
of RANTES and was, for CCR1, higher (
 
K
 
i 
 
0.023 
 
6
 
 0.007
nM) than that of MIP-1
 
a
 
. The affinity for CCR3 (
 
K
 
i
 
 2.7 
 
6
 
0.8 nM) was 
 
z
 
10-fold lower than that of eotaxin. Full size
HCC-1 tested in parallel in functional and binding studies
appeared as a fairly weak agonist of CCR1 (
 
K
 
i
 
 
 
.
 
 100 nM)
and was totally inactive on CCR5, in agreement with pre-
Figure 1. Purification of HCC-1[9–74] from human hemofiltrate. (a)
A fraction resulting from cation exchange chromatography was applied to
RP-HPLC, and the biological activity of the fractions on human CCR5
was assayed (dotted line). (b) Fifth and final purification step of the active
material by RP-HPLC. The active peak (dotted line) was analyzed by
mass spectrometry and Edman degradation. (c) Time course of the
CCR5-stimulatory activity generated by tryptic digestion of HCC-1. (d)
RP-HPLC chromatogram of trypsin-digested HCC-1 (1-h incubation),
showing the generation of HCC-1[9–74] (shaded). (e) Amino acid se-
quence of the NH2-terminal part of HCC-1, HCC-1[9–74], HCC-3,
and other chemokines active on CCR1, CCR3, or CCR5. Asterisks
mark the first two conserved cysteines. 
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vious reports (19, 21). It was found to compete partially for
eotaxin binding on CCR3, despite the absence of func-
tional response of this receptor (Fig. 2 b).
The biological activity of HCC-1[9–74] was further
tested on natural cell populations for its calcium mobiliza-
tion and chemotactic properties. In monocytes, HCC-1[9–
74] induced robust calcium fluxes, comparable to those
evoked by RANTES (Fig. 3 a). 50 nM HCC-1[9–74] to-
tally desensitized these cells to further stimulation by the
same ligand (data not shown) and abrogated further re-
sponse to 50 nM RANTES as well, whereas HCC-1[9–74]
remained capable of mobilizing calcium at reduced levels
after a first stimulation by up to 100 nM RANTES (Fig. 3
a). Prior stimulation by HCC-1[1–74] did not modify the
response to HCC-1[9–74], whereas a first stimulation by
MIP-1
 
b
 
 (50 nM) resulted in a mild calcium mobilization
response with no reduction of the subsequent response to
HCC-1[9–74] (data not shown). Similar results were ob-
tained with the monocytic cell line THP-1 (not shown). In
chemotaxis assays with monocytes, HCC-1[9–74] was as
potent (maximal migration observed at 10 nM) and effi-
cient as RANTES. It was 100-fold more potent than full
size HCC-1, which appeared as a weak but efficient
chemoattractant (19). MIP-1
 
b
 
 had weak or no chemotactic
activity on monocytes, depending on the donors (Fig. 3 a).
These results suggest that CCR1 mediates most of the
functional response of monocytes to HCC-1[9–74] but
that CCR5 and other as yet unidentified receptor(s) may
also contribute to this activity.
HCC-1[9–74] mobilized calcium less efficiently than eo-
taxin in eosinophils (Fig. 3 b). The eotaxin response was
slightly reduced after prior exposure to HCC-1[9–74],
whereas the activity of HCC-1[9–74] was unaltered after
eotaxin stimulation (Fig. 3 b) and strongly inhibited after
MIP-1
 
a
 
 stimulation (data not shown). These results sub-
stantiate the role of HCC-1[9–74] as a weak agonist of
CCR3 and support the involvement of CCR1 in the func-
tional response of eosinophils to HCC-1[9–74]. In chemo-
taxis assays, HCC-1[9–74] was less potent but almost as ef-
ficacious as eotaxin on eosinophils from most donors. For
one of the donors, however, HCC-1 was weakly chemo-
tactic at high concentrations only (data not shown), which
was attributed to the low CCR1 expression observed on
eosinophils from some individuals (32). HCC-1[9–74] but
not full size HCC-1 mobilized calcium in IL-2–condi-
tioned lymphoblasts. Complete cross-desensitization was
observed between the responses to HCC-1[9–74] and
MIP-1
 
b
 
, indicating that CCR5 is the principal receptor
used by HCC-1[9–74] in these cells. Migration of lympho-
blasts was stimulated by HCC-1[9–74] and MIP-1
 
a
 
 but
not by full size HCC-1 (Fig. 3 c).
Given the role of CCR5 as the major coreceptor for
macrophage-tropic strains of HIV (11–14) and the role as-
cribed to chemokines acting on CCR5 as entry inhibitors
Figure 2. Binding and functional activity of HCC-1[9–74] on human
recombinant receptors expressed in CHO-K1 cells. Competition binding
assays (left panels) and functional aequorin-based assays (right panels) were
performed with CCR1 (a), CCR3 (b), and CCR5 (c). HCC-1[9–74]
(n), HCC1[1–74] (m), MIP-1a (h), RANTES (s), Eotaxin (j), and
MCP-4 (.) were used as ligands in both assays. Binding and functional
assay results are representative of at least three independent experiments.
The data represent the mean and SEM for measurements performed in
triplicate.
 
Table I.
 
Binding and Functional Parameters of CCR1, CCR3, and CCR5 for Full Size HCC-1, HCC-1[9–74], and Reference 
Chemokines for Each Receptor
 
CCR1 CCR3 CCR5
Ligand
 
K
 
i
 
 
 
6
 
 SEM EC
 
50
 
 
 
6
 
 SEM
 
K
 
i
 
 
 
6
 
 SEM EC
 
50
 
 
 
6
 
 SEM
 
K
 
i
 
 6 SEM EC50 6 SEM
HCC-1 .100 .1,000 .1,000 .1,000 .1,000 .1,000
HCC-1[9–74] 0.023 6 0.007 2.8 6 0.8 2.7 6 0.8 78 6 14 0.04 6 0.01 4.8 6 1.2
RANTES ND 6.3 6 1.1 ND 15 6 4 0.05 6 0.01 2.4 6 0.5
MIP-1a 0.32 6 0.06 15 6 5 ND ND 0.11 6 0.06 3.3 6 0.8
MIP-1b ND ND ND ND ND 1.3 6 0.5
Eotaxin ND ND 0.31 6 0.03 2.4 6 0.4 ND ND
Values, expressed in nM, are the mean and SEM for at least three independent determinations.1505 Detheux et al.
(15), we investigated the antiviral activity of HCC-1[9–74]
in an infection inhibition assay. Both HCC-1[9–74] and
RANTES inhibited infection by the macrophage-tropic
strain YU2 (Fig. 4 a). RANTES reduced YU2 infection of
P4-CCR5 cells by .95% at 3.2 mM and by 50% at 1.3
mM. HCC-1[9–74] was slightly more efficient, blocking
YU2 infection by 50% at 0.5 mM. Similar results were ob-
tained using the macrophage-tropic strain JR-CSF (not
shown). No inhibitory effect on YU2 infection was ob-
served with full-length HCC-1. None of the three
chemokines inhibited the T-tropic strain NL4-3 (Fig. 4 b).
In agreement with previously published results (33),
RANTES enhanced infectivity of NL4-3 by z50% at con-
centrations over 0.6 mM. In contrast, no enhancing effect
on infectivity was observed with HCC-1[9–74] (Fig. 4 b).
We also tested whether HCC-1[9–74] could inhibit HIV-1
replication in human PBMCs. As shown in Fig. 4, c and d,
replication of the macrophage-tropic strain JR-CSF was
blocked significantly by HCC-1[9–74] and RANTES at
concentrations of 125 nM, whereas concentrations of 625
nM were necessary for the YU2 strain. No inhibition of
NL4-3 replication was observed, and full size HCC-1 was
ineffective for all strains (not shown).
Considering the ability of trypsin to generate HCC-1[9–
74] in vitro, we hypothesized that other and potentially
more specific proteases could be involved in the in vivo
processing of HCC-1. As tumor cells are known to release
a number of proteases active on extracellular matrix and
mediators, we tested conditioned media from a set of hu-
man tumor cell lines for HCC-1 processing activities using
the CCR5-expressing cell line as a bioassay. The prostate
carcinoma cell line DU-145 (34), the osteosarcoma cell line
143B, the mammary adenocarcinoma cell line MCF-7
(35), and the melanoma cell line MeWo (36) were used as
sources of proteases potentially involved in the activation of
HCC-1. Incubation of 1 mM HCC-1 in the medium of
monolayer cell cultures generated a clear CCR5-stimula-
tory activity for the cell lines DU-145 and 143B (Fig. 5 a).
Weak activities were recovered from MCF-7 and MeWo
supernatants. A CCR5-stimulatory activity was also ob-
tained when HCC-1[1–74] was incubated with acellular
conditioned medium from DU-145 cells (data not shown).
Preliminary time course experiments indicated that maxi-
mal activity was reached after 10 h of incubation in these
conditions, after which a plateau was maintained for over
24 h (data not shown). Based on this maximal activity, it
was estimated that up to 10% of HCC-1 was converted
Figure 3. Calcium mobilization and chemotaxis induced by HCC-
1[9–74] in primary cell populations. Monocytes (a), eosinophils (b), and
IL-2–stimulated lymphoblasts (c) were tested for their functional response
to HCC-1[9–74], full size HCC-1, and reference chemokines. Stimula-
tion of calcium mobilization and cross-desensitization experiments (left
panels) were performed with 50 nM chemokine concentrations. For
chemotaxis assays (right panels), cell migration in response to HCC-1[9–
74] (n), HCC-1 (m), RANTES (s), Eotaxin (j), or MIP-1b (d) is re-
ported as a migration index. Each panel is representative of at least three
independent experiments. The chemotaxis data represent means and SEM
for triplicate wells.
Figure 4. Inhibition of HIV-1 infection. Cells expressing both CCR5
and CXCR4 coreceptors were infected with the YU2 strain (a), which
uses CCR5, and the NL4-3 strain (b), which uses CXCR4, in the pres-
ence of full size HCC-1 (m), HCC-1[9–74] (n), or RANTES (h). The
data represent the mean and SEM for points performed in triplicate. Hu-
man PBMCs were infected with JR-CSF (c) and YU-2 (d) in the pres-
ence of RANTES (black bars) or HCC-1[9–74] (gray bars). The data
represent the reverse transcriptase activity measured in culture cell super-
natants harvested 10 d (JR-CSF) or 14 d (YU-2) after infection. Results
are expressed as photostimulated luminescence (PSL) units.1506 Truncated HCC-1 Is a CCR1 and CCR5 Agonist
into a CCR5-activating form by proteolysis during the in-
cubation. We next tested whether inhibitors of various
protease families could inhibit what was expected to repre-
sent the proteolytic processing of inactive HCC-1. HCC-
1[1–74] (200 nM) was coincubated with protease inhibitors
in serum-free conditioned medium from the DU-145 cell
line (Fig. 5 b). AEBSF (4-[2-aminoethyl]-benzylsulfonyl
fluoride), an inhibitor of serine proteases, and leupeptin, an
inhibitor of serine and cysteine proteases, reduced the acti-
vation of HCC-1 by z75% to near control levels. Other
serine protease inhibitors, such as aprotinin and a2-macro-
globulin, the soybean trypsin inhibitor, an inhibitor of cys-
teine proteases (E-64), as well as inhibitors of metallo-
proteases (EDTA, 1,10-phenanthroline) and of aspartic
proteases (pepstatin) had weak (,10% of inhibition) or no
effects on the generation of CCR5-stimulatory activity.
Discussion
We have shown in this work that a truncated variant of
HCC-1, HCC-1[9–74], acts as a high-affinity agonist on
CCR1, CCR5, and, to a lesser extent, CCR3. Using cal-
cium mobilization and chemotaxis assays, we have shown
that HCC-1[9–74] is active on monocytes, and our data
suggest that CCR1 is the main receptor involved in the
functional response of these cells, in accordance with the
weak expression of CCR5 found in freshly prepared
monocytes (11). CCR1 was also identified as mediating the
effects of HCC-1[9–74] on eosinophils, whereas the func-
tional response of T lymphoblasts was attributed to CCR5,
in agreement with the high expression of this receptor on
these cells (37, 38). As expected for a potent CCR5 ago-
nist, HCC-1[9–74] acted as an efficient blocker of HIV en-
try, with a potency similar to that of RANTES, the most
efficient natural chemokine so far. Full size HCC-1, pro-
duced constitutively by numerous tissues and present in
normal human plasma, was inactive in all assays, with the
exception of its modest activity on CCR1.
We therefore propose that HCC-1 represents an inactive
precursor that can be processed by proteases to an active
chemokine, able to recruit monocytes/macrophages, T
lymphocytes, and eosinophils through CCR1, CCR3, and
CCR5 and possibly other receptors that remain to be char-
acterized. Limited proteolysis by trypsin in vitro was able to
generate the truncated chemokine, which was also ex-
tracted from a natural source, human hemofiltrate. Further-
more, conditioned media from the prostatic adenocarci-
noma cell line DU-145 and the osteosarcoma cell line 143-B
were shown to contain an activity able to process HCC-1
into a form that could activate CCR5. The inhibition
profile obtained with the DU-145 cell line suggests that
this activity is mediated by a serine protease. We speculate
that the result of this processing is the generation of HCC-
1[9–74], which is consistent with the cleavage downstream
of an arginine residue. Future work will aim at demonstrat-
ing this fact. We will also investigate whether the release of
HCC-1–activating proteases is shared by a broader range of
human tumoral cell lines. The precise nature of the pro-
tease(s) responsible for the cleavage in conditioned media
and in vivo remains to be determined, but various trypsin-
like serine proteases, many of which are known to be acti-
vated in the course of inflammatory or tumoral processes,
could be involved.
Thus, HCC-1[9–74] represents the naturally processed,
biologically active form of the human chemokine HCC-1.
HCC-3, a splice variant of HCC-1 with a different NH2
terminus (Fig. 1 e; reference 17), might also generate
HCC-1[9–74] by proteolytic cleavage, although the argi-
nine present at the cleavage site of HCC-1 is not conserved
in HCC-3. From the relative recovery of HCC-1[1–74]
and HCC-1[9–74] during the purification procedure from
human hemofiltrate, we estimate that the concentration of
HCC-1[9–74] in hemofiltrate (and presumably in plasma)
might be 100–1,000-fold lower than that of HCC-1[1–74].
Local concentrations of HCC-1[9–74] might, however, be
significantly higher at specific sites or under specific patho-
physiological situations, depending on the expression and/
or activation of the protease(s) responsible for the process-
ing of the abundant HCC-1[1–74].
Proteolytic processing has been described for other
chemokines. Neutrophil-activating peptide 2, a neutrophil
chemoattractant, is processed from two platelet-specific
precursors by the action of cathepsin G (39, 40). Dipeptidyl
peptidase IV (CD26) removes the NH2-terminal dipeptide
from various chemokines (RANTES, stromal cell–derived
factor 1, macrophage-derived chemokine, eotaxin), usually
resulting in a reduction of their biological activities (25, 41,
42). The processing of HCC-1 is unique, however, as
HCC-1 is widely expressed in tissues and abundant in
plasma, and its proteolytic processing transforms an almost
inactive precursor to a wide-range chemoattractant. This
mechanism therefore represents an alternative to transcrip-
Figure 5. Generation of CCR5-
stimulatory activities from HCC-1
[1–74] by conditioned media from
human tumor cell lines. CHO-K1
cells coexpressing CCR5 and
apoaequorin were used to test the
biological activity generated from
HCC-1[1–74] in conditioned
media. (a) The medium from
monolayer cultures of the cell lines
DU-145, 143B, MCF-7, and
MeWo, incubated without (gray
bars) or after addition of 1 mM
HCC-1[1–74] (white bars), was
tested for CCR5-stimulatory ac-
tivities. (b) Conditioned medium
from the DU-145 cell line (gray
bar) was incubated with 200 nM
HCC-1[1–74] alone (black bar) or
in the presence of various protease
inhibitors: aprotinin (0.3 mM), leupeptin (1 mM), AEBSF (4 mM), soy-
bean trypsin inhibitor (5 mM),  a2-macroglobulin (20 nM), 1,10-
phenanthroline (10 mM), EDTA (1 mM), pepstatin (1 mM), and E-64
(N-[N-[l-3-trans-carboxirane-2-carbonyl]-l-leucyl]-agmatine, 2.5 mM).
The results in RLU represent the mean and SEM of triplicate data points
and are representative of two independent experiments. Cont. Med.,
conditioned medium without added HCC-1[1–74].1507 Detheux et al.
tional control for the generation of inflammatory chemo-
kines. It also appears to couple leukocyte recruitment to
the proteolytic pathways activated in tissue remodeling and
tumors (6).
When tested in parallel under highly stringent condi-
tions, using high doses of virus and fully activated PBMCs,
HCC-1[9–74] and the most potent natural HIV-1 inhibi-
tor known thus far, RANTES, showed comparable inhibi-
tory activities. As the concentration of HCC-1 in normal
human plasma is z10-fold higher than that of RANTES
(43), the conversion of this precursor into the active
chemokine HCC-1[9–74] might affect HIV-1 replication
in infected individuals and play an important role in AIDS
pathogenesis. Modifications of HCC-1, such as additional
truncations or NH2-terminal modifications, similar to what
has been performed for RANTES, might generate more
active agonists or antagonists with enhanced interest as
anti-HIV molecules (44, 45). Delayed progression to AIDS
has been correlated to high levels of chemokines acting at
CCR5 (46). Nevertheless, chemokines and analogues have
strong limitations as therapeutic agents given the size of the
molecules, their production costs, and the need for re-
peated parenteral delivery. However, given the abundance
of full size HCC-1 in normal human plasma (17), it may be
considered to induce the conversion of this precursor into
the active chemokine HCC-1[9–74], thus generating in
vivo an efficient blocker of HIV entry.
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